Notícias Editas Medicine Inc - EDIT | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Editas Medicine Inc (EDIT)
Editas Medicine Inc (EDIT) Notícias

Editas Medicine Inc (EDIT)

1,22

-0,02

(-1,61%)

Fechado 20 Janeiro 6:00PM

Atrasado por 15 minutos

1,22

0,00

(0,00%)

Após o horário de negociação: 9:58PM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Form 8-K - Current report

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Form 8-K - Current report

Form 8-K - Current report

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Editas Medicine to Participate in Upcoming Investor Conferences

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Form 8-K - Current report

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Editas Medicine

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições